Kmpharmaceutical

At a glance

Kmpharmaceutical filed 86 disclosures in the last 12 months, including 26 insider, 19 5% holder, 1 buyback and 1 issuance. The most recent key filing was on Oct 8: A major holder's stake rose from 49.66% to 49.66% (share lending).

Revenue for 2025 was ₩16B, up 10.5% on 2024. It made an operating loss of ₩2.9B. Debt was 64% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩8.3B and operating loss of ₩1.2B.

The 2025 annual report lists 63 employees with an average tenure of 4.3 years and average pay of ₩42.8M, #1701 of 1,829 listed companies by average pay. Its 10 directors and auditors were paid ₩478M each on average. It paid no cash dividend for 2025. 강일모 and related parties held 38.79% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 49.66% on Oct 8.

From the 2025 annual report

Staff: 63 (33 men, 30 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩2.7B. Directors and auditors: 10, paid ₩1.6B in total.

No cash dividend was paid for 2025.

Largest shareholder

강일모 holds 37.29%; with 1 related party the group holds 38.79% of common shares at year end.

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports